Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Roivant announced positive Phase 2 trial results for mosliciguat, demonstrating improved walk distance and reduced cardiac strain in PH-ILD.
Roivant's medicine for a rare lung disease showed it actually works better than expected in patient tests. When a company proves their medicine helps people, investors get more hopeful about whether the company will succeed and make money in the future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.